Search

everythinglearnresearchcommunity

for

Search:↓

No link found between specific genes and female pattern hair loss.

The conclusion is that proper evaluation and treatment of hair loss in midlife women is important, considering the emotional impact and potential for various treatments.

Hormone imbalances can cause skin diseases, and understanding these links is important for diagnosis and treatment.

FPHL is common in women, influenced by genetics and hormones, and can be treated with medications, laser therapy, or hair transplantation.

Hormones and genes affect hair growth and male baldness.

Hormones affect skin aging and fat distribution, and treatments can help, but only minoxidil is proven for female hair loss.

Skin diseases linked to insulin resistance should be managed to prevent diabetes and reduce heart disease risk.

Estrogen and prolactin may play bigger roles in female hair loss than previously thought.

New treatments for enlarged prostate are being developed to be more effective and have fewer side effects.

Early diagnosis and personalized treatment for PCOS are crucial, especially for young women in West Bengal, India.

Thyroid hormones and androgens affect gene expression in frog reproductive organs differently between males and females.

Testosterone helps prevent skin damage in males by acting through both estrogen and androgen pathways.

Bolandiol, a synthetic steroid, builds muscle and bone without greatly affecting sex glands, and works differently from other hormones.

Estrogens are key for bone growth spurts in both boys and girls and affect growth into adulthood.

New hormonal treatments for enlarged prostate show promise for safer, effective non-surgical options.

Bisphenol-A (BPA) increases connections between brain cells and boosts their activity, but it blocks the effects of a male hormone on brain cell plasticity.

The document concludes that hormone therapy is essential for treating gender dysphoria, with specific drugs and monitoring protocols recommended for safety and effectiveness.

The document concludes that treating androgen excess needs patience, managing expectations is important, and many drugs used are not officially approved, suggesting cosmetic options for mild cases.

A 17-year-old female with adrenogenital syndrome produces very high levels of androgens, which prevent complete feminization despite high estrogen doses.

17β-estradiol lowers polyamine oxidase levels in breast cancer cells through estrogen receptor 2.

Finasteride treatment changes urine metabolomics and steroid signatures, potentially monitoring effectiveness but may cause sexual side effects.

The medication combination did not affect glucose tolerance but increased some cholesterol levels due to its estrogen component.

Transdermal testosterone can improve sexual desire in postmenopausal women but lacks long-term safety data and is not FDA-approved for this use.

Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.

Testosterone replacement may help postmenopausal women with sexual function and bone density, but suitable treatments are limited.

Testosterone therapy can improve sexual satisfaction and mood in surgically menopausal women when used with estrogen, but its long-term safety and effects on naturally menopausal and premenopausal women are unclear.

Finasteride use may be linked to rare testicular tumor, but more research needed.

Certain drugs, especially antiandrogens and spironolactone, significantly increase the risk of gynecomastia.

A woman with anorexia and Cushing's syndrome improved after tumor removal, highlighting the need to consider hormonal issues in psychiatric conditions.

Hair loss causes differ between men and women due to changes in hormone levels and inflammation-related pathways.